Blood:树突细胞来源的IL-6失调介导alloSCT后移植物抗宿主病的发生

2020-01-02 不详 MedSci原创

中心点:DCs是异体移植后IL-6失调的主要来源。IL-6依赖性GVHD受供体T细胞上的IL-6R经典信号驱动,但受反式信号调控。摘要:异体干细胞移植(alloSCT)后移植物抗宿主病(GVHD)的特点是白细胞介素-6 (IL-6)调节异常。IL-6可以通过多种途径介导作用,包括经典、反式和簇信号。鉴于近年来有多种药物可以抑制这些离散的信号级联,了解细胞因子的来源、信号和细胞靶点对临床研究的设计至

中心点:

DCs是异体移植后IL-6失调的主要来源。

IL-6依赖性GVHD受供体T细胞上的IL-6R经典信号驱动,但受反式信号调控。

摘要:

异体干细胞移植(alloSCT)后移植物抗宿主病(GVHD)的特点是白细胞介素-6 (IL-6)调节异常。IL-6可以通过多种途径介导作用,包括经典、反式和簇信号。鉴于近年来有多种药物可以抑制这些离散的信号级联,了解细胞因子的来源、信号和细胞靶点对临床研究的设计至关重要。

在本研究中,研究人员发现受体树突细胞(DCs)分泌的IL-6可引发这种细胞因子的系统性失调。在T细胞中,通过靶向敲除IL-6受体(IL-6R)抑制DC驱动的经典信号可消除致病性供体Th17/Th22细胞分化,进而获得长期存活。移植后,供体DCs承担同样的角色,维持经典IL-6信号依赖性GVHD反应。

意外的是,移植后的集束信号并不活跃,而用可溶性gp130Fc抑制反式信号可促进严重的、慢性皮肤GVHD的发生。后者是多功能性Th22细胞过度增殖的结果,IL-22缺失或IL-6R抑制可逆转这一结果。重要的是,抑制IL-6经典信号并不影响移植物抗白血病的效果。

总而言之,本研究结果强调了IL-6信号和下游Th17/Th22分化可作为alloSCT后的重要治疗靶点。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1693295, encodeId=a51a169329543, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Tue May 05 06:17:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745336, encodeId=d7391e4533697, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sat Jan 04 09:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273786, encodeId=cf3c12e378688, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329322, encodeId=3b3a1329322f6, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404733, encodeId=56d31404e33b6, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419729, encodeId=a9f61419e29f5, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620746, encodeId=cd571620e469d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1693295, encodeId=a51a169329543, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Tue May 05 06:17:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745336, encodeId=d7391e4533697, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sat Jan 04 09:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273786, encodeId=cf3c12e378688, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329322, encodeId=3b3a1329322f6, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404733, encodeId=56d31404e33b6, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419729, encodeId=a9f61419e29f5, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620746, encodeId=cd571620e469d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
    2020-01-04 xuyong535
  3. [GetPortalCommentsPageByObjectIdResponse(id=1693295, encodeId=a51a169329543, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Tue May 05 06:17:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745336, encodeId=d7391e4533697, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sat Jan 04 09:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273786, encodeId=cf3c12e378688, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329322, encodeId=3b3a1329322f6, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404733, encodeId=56d31404e33b6, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419729, encodeId=a9f61419e29f5, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620746, encodeId=cd571620e469d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
    2020-01-04 kzlchina
  4. [GetPortalCommentsPageByObjectIdResponse(id=1693295, encodeId=a51a169329543, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Tue May 05 06:17:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745336, encodeId=d7391e4533697, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sat Jan 04 09:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273786, encodeId=cf3c12e378688, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329322, encodeId=3b3a1329322f6, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404733, encodeId=56d31404e33b6, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419729, encodeId=a9f61419e29f5, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620746, encodeId=cd571620e469d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
    2020-01-04 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=1693295, encodeId=a51a169329543, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Tue May 05 06:17:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745336, encodeId=d7391e4533697, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sat Jan 04 09:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273786, encodeId=cf3c12e378688, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329322, encodeId=3b3a1329322f6, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404733, encodeId=56d31404e33b6, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419729, encodeId=a9f61419e29f5, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620746, encodeId=cd571620e469d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
    2020-01-04 wincls
  6. [GetPortalCommentsPageByObjectIdResponse(id=1693295, encodeId=a51a169329543, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Tue May 05 06:17:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745336, encodeId=d7391e4533697, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sat Jan 04 09:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273786, encodeId=cf3c12e378688, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329322, encodeId=3b3a1329322f6, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404733, encodeId=56d31404e33b6, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419729, encodeId=a9f61419e29f5, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620746, encodeId=cd571620e469d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1693295, encodeId=a51a169329543, content=<a href='/topic/show?id=51836199472' target=_blank style='color:#2F92EE;'>#树突细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61994, encryptionId=51836199472, topicName=树突细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b5f29361937, createdName=daviiliu, createdTime=Tue May 05 06:17:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745336, encodeId=d7391e4533697, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Sat Jan 04 09:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273786, encodeId=cf3c12e378688, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329322, encodeId=3b3a1329322f6, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404733, encodeId=56d31404e33b6, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1419729, encodeId=a9f61419e29f5, content=<a href='/topic/show?id=a798e520582' target=_blank style='color:#2F92EE;'>#移植物抗宿主病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75205, encryptionId=a798e520582, topicName=移植物抗宿主病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d6c3527534, createdName=手留余香, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620746, encodeId=cd571620e469d, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sat Jan 04 05:17:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]

相关资讯

Blood:树突细胞不能正常激活CD4 T细胞时可导致骨髓增生

中心点:骨髓增生可能是DC-CD4 T细胞相互作用缺陷以及DCs数目缺陷的结果。摘要:树突细胞(DCs)是适应性免疫应答起始的关键细胞。近期,有研究提示DCs具有抑制骨髓增殖的作用。在构成性敲除DCs的小鼠研究和由GATA2或IRF8突变引起DCs先天性缺陷的患者中均可观察到骨髓增生性疾病(MPD)。DC缺陷和MPD之间的机制关联尚不明确。目前流行的模型表明数目性树突细胞缺陷通过代偿性髓系分化导致

Int Arch Allergy Immunol:Zeste同源体2增强子的表观修饰能够调节树突细胞的激活

过敏原免疫疗法(AIT)是目前过敏性鼻炎(AR)唯一的病因学和可能的治愈疗法。最近,有研究人员探索调查了AIT中,表观调节因子zeste同源体2增强子(EZH2)在树突细胞(DCs)激活中的作用。研究包括了56名AR患者的临床信息,他们均接受了AIT治疗。其中,30名受试者进行的是皮下免疫治疗(SCTI),26名受试者进行的是舌下免疫治疗(SLIT)。研究发现,EZH2的表达在循环mDCs和pDC

Mol Med Rep:树突细胞中CD86的沉默能够调控过敏性鼻炎患者T细胞中细胞因子的产生

最近,有研究人员在来源于过敏性鼻炎(AR)患者的外周血样中调查了共刺激分子T淋巴细胞活化抗原CD86在树突细胞(DCs)中的表达和作用,并与那些来源于健康个体的样本进行了比较。研究发现,与对照组相比,来源于AR患者外周血样本的成熟DCs细胞表达更高水平的共刺激分子CD86,而不是CD80。CD86在DCs中的表达水平在转染了慢病毒载体siRNA后显著减少。更多的是,与DCs细胞共培养的T细胞产生的

Blood:体外激活和依鲁替尼治疗可恢复CLL Vγ9Vδ2-T细胞的抗CLL细胞的细胞毒性作用

中心点:健康的Vγ9Vδ2-T细胞可识别裂解CLL细胞,但CLL患者来源的Vγ9Vδ2-T细胞的细胞毒性和细胞因子合成受损。用自体moDCs在体外激活Vγ9Vδ2-T细胞可逆转其功能障碍,依鲁替尼可促进产生抗肿瘤的TH1表型。摘要:自体(αβ)T细胞为基础的治疗策略用于慢性淋巴细胞白血病(CLL)的疗效一直较为温和。具有强力的抗淋巴瘤活性的细胞毒性T淋巴细胞通过主要组织相容性复合物(MHC)非依赖

Blood:树突细胞的IL-6失调通过经典信号传导引发移植物抗宿主病

同种异体干细胞移植(alloSCT)后移植物抗宿主病(GVHD)的特点是白细胞介素6 (IL-6)调节异常。IL-6可通过多种途径介导其作用,包括经典、反式和群集信号。鉴于近年来有多种药物可以抑制这些离散信号级联,了解细胞因子的来源、信号和细胞靶点对临床研究的设计至关重要。Wilkinson等人发现受体树突细胞(DC)分泌的IL-6启动了这种细胞因子的系统失调。靶向敲除T细胞中的IL-6受体(IL

J Allergy Clin Immunol:髓样树突状细胞和浆细胞样树突状细胞对过敏性鼻炎患者ILC2s的影响研究

Ⅱ型固有淋巴细胞(ILC2s)在过敏性疾病中具有关键的作用。髓样树突状细胞(mDCs)和浆细胞样树突状细胞(pDCs)在过敏性免疫响应中也有明显的作用。然而,DCs对ILC2s在过敏性疾病中的影响,尤其是过敏性鼻炎患者中,仍旧不清楚。最近,有研究人员评估了在AR中mDCs和pDCs在调控ILC2功能中的作用。研究发现,ILC2s、mDCs和pDCs在AR患者的鼻粘膜中的确存在。异体和自体mDCs均